Serum opsonic activity for Haemophilus influenzae type b in infants immunized with polysaccharide-protein conjugate vaccines.
Serum opsonic activity for Haemophilus influenzae type b in infants immunized with polysaccharide-protein conjugate vaccines.
复制标题
用多糖-蛋白结合疫苗免疫的婴儿中 b 型流感嗜血杆菌的血清调理活性。
DOI：
10.1093/infdis/152.5.1076
复制
发表时间：
1985
期刊：
影响因子：
--
通讯作者：
Cates Kl
中科院分区：
文献类型：
--
作者：
Cates Kl
b型流感嗜血杆菌(Hib)-多糖疫苗在小于18-24月龄的儿童中是一种较差的免疫原，而18-24月龄的儿童是侵袭性Hib疾病的最高风险群体。因此，人们为开发多糖-蛋白结合疫苗做出了广泛的努力[2,3]。这些结合疫苗似乎在实验动物[2,3]和人类[4-6]中都比纯化多糖（PRP）疫苗具有更强的免疫原性。该实验室先前的一项研究表明，成人接种Hib多糖-白喉类毒素（PRP-D）结合疫苗可导致血清中Hib蛋白活性增加。此外，血清中opsonic活性水平与放射性抗原结合试验测定的抗囊抗体浓度成正比。由于婴儿对多糖疫苗的特异性同型和可能的独特型反应可能不同于年龄较大的儿童或成人[6,8]，并可能影响产生的抗体的功能活性[9,10]，我们检测了9至13个月大的婴儿由PRP或PRP- d疫苗诱导的血清opsonic活性。14名婴儿接受了两剂PRP- d， 14名接受了两剂PRP疫苗，第一次和第二次接种间隔一个月，作为这些疫苗的安全性和免疫原性研究的一部分。这两种疫苗均由Connaught Laboratories （Swiftwater, Pa）提供，并被描述为[4]。接种前和每次接种后1个月采集血清样本。为我们的研究选择血清样本是基于可获得性。从每组接种疫苗的14名婴儿中获得的刺激前或刺激后血清中PRP抗体的几何平均浓度（表1）与原始的28名PRP- d和27名PRP疫苗接种者的血清中抗体的几何平均浓度之间没有显著差异。本研究中使用的调理吞噬作用方法已被详细描述[b]。该试验测量疫苗接种者血清增强健康成人外周血PMNLs对[3H]胸腺嘧啶标记Hib吸收的能力。所有血清在使用前均经过热灭活处理
Haemophilusinfluenzaetype b (Hib)-polysaccharide vaccine is a poor immunogen in children< 18-24 months of age [1], the group at highest risk for invasive Hib disease. For this reason, extensive efforts have been made to develop polysaccharide-protein conjugate vaccines [2, 3]. These conjugate vaccines appear to be more immunogenic in both experimental animals [2, 3] and humans [4-6] than the purified polysaccharide (PRP) vaccine. A previous study from this laboratory [7] demonstrated that immunization of adults with a Hib polysaccharide-diphtheria toxoid (PRP-D) conjugate vaccine led to an increase in opsonic activity in the serum for Hib. Furthermore, the levels of opsonic activity in serum were directly proportional to the concentrations of anticapsular antibody as measured by radioantigen-binding assay. Because specific isotype and, possibly, idiotype responses of infants to polysaccharide vaccinesmay differ from those of older children or adults [6, 8] and potentially affect functional activity of the antibody produced [9, 10], we examined serum opsonic activity induced by PRP or PRP-D vaccine in nineto 13-month-old infants.Fourteen infants received two doses of PRP-D, and 14 received two doses of PRP vaccine, the first and second doses administered one month apart as part of a study of the safety and immunogenicity of these vaccines [6]. Both vaccines were supplied by Connaught Laboratories (Swiftwater, Pa) and have been described [4]. Serum samples were obtained before immunization and one month after each dose. Selection of serum samples for our study was based on availability. There was no significant difference between the geometric mean concentration of antibody to PRP of pre-or postimmunization sera obtained from the 14infants in each group ofvaccinees studied (table 1) and those of the original 28 PRP-D and 27 PRP vaccine recipients, respectively [6]. The method for opsonophagocytosis employed in this study has been described in detail [7]. This assay measures the ability of serum from vaccine recipients to enhance uptake of [3H] thymidine-Iabeled Hib by PMNLs obtained from peripheral blood of healthy adults. All sera were heat inactivated before use and tested in